Table 2

Demographic and virological characteristics of the study population

CharacteristicPatients with SOF/VEL±RBVPatients with GLE/PIBP-value
Population, % (n)60.5% (46)39.5% (30)
Males, % (n)78.3% (36)66.7% (20)0.39
Age, mean (years±SD)48,72±9,4147,03±11,320.5
Age≥65 years, % (n)4.3% (2)6.6% (2)0.93
HIV co-infection, % (n)13.0% (6)0.0% (0)0.1
Fibrosis stage, % (n)
 F0-154.3% (25)53.3% (16)0.88
 F219.6% (9)16.7% (5)0.99
 F36.5% (3)20.0% (6)0.16
 F419.6% (9)10.0% (3)0.43
Previous clinical decompensation, % (n)2.2% (1)0.0% (0)0.83
CTP classification, % (n)
 A19.6% (9)10.0% (3)0.43
 B0.0% (0)0.0% (0)>0.99
 C0.0% (0)0.0% (0)>0.99
Hepatocellular carcinoma, % (n)4.3% (2)0.0% (0)0.67
Liver transplant, % (n)2.2% (1)0.0% (0)0.83
HCV viral load, log UI/mL (mean±SD)6,13±0.805,97±0.950.45
Estimated glomerular filtration rate<60 mL/min, % (n)2.2% (1)0.0% (0)0.83
Previous antiviral treatment, % (n)
 Naïve93,5% (43)90,0% (27)0.91
 Treatment-experienced6,5% (3)10% (3)
Response to previous antiviral treatment, % (n)
 Recidivant0.0% (0)6.7% (2)0.3
 Reinfection2.2% (1)0.0% (0)0.83
 Null responder2.2% (1)0.0% (0)0.83
 Unknown2.2% (1)3.3% (1)0.67
  • CPT, Child-Pugh-Turcotte; GLE/PIB, glecaprevir/pibrentasvir; HCV, hepatitis C virus; HIV, human immunodeficiency virus; SOF/VEL±RBV, sofosbuvir/velpatasvir±ribavirin.